Key result
Shikimic acid significantly ameliorated doxorubicin-induced cardiotoxicity in rats, reducing CK-MB levels from 596.56 U/L to 312.48 U/L and restoring antioxidant defenses.
Why the study?
Doxorubicin is effective against malignancies but limited by cardiotoxicity, prompting investigation into the protective effects of shikimic acid.
Does shikimic acid prevent doxorubicin-induced cardiotoxicity in male rats?
Population
Fifty male rats
Comparison
Negative control vs DOX vs SA vs DOX plus SA
Design
Preclinical animal and in silico study
Follow-up
A month
Authors
Loading...
Should not change practice; hypothesis-generating for shikimic acid in doxorubicin cardiotoxicity.
Does shikimic acid prevent doxorubicin-induced cardiotoxicity in male rats?
Absolute Event Rate: 312.48% vs 596.56%
p-value: p=<0.001
Shikimic acid mitigates doxorubicin-induced cardiotoxicity in rats by targeting the Nrf-2/Keap-1/HO-1/NQO-1 signaling pathway, suggesting potential as a cardioprotective adjunct in chemotherapy.
Alwaili et al. (2025) studied Doxorubicin-induced cardiotoxicity (n=50). Shikimic acid vs. Doxorubicin alone (4 mg/kg i.p. once a week) was evaluated on CK-MB levels (U/L) (p=<0.001). Shikimic acid significantly ameliorated doxorubicin-induced cardiotoxicity in rats, reducing CK-MB levels from 596.56 U/L to 312.48 U/L and restoring antioxidant defenses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: